Ventac Partners manages a successful FDA pharmaceutical audit of the manufacturing facility of a European client commercializing a series of non-sterile prescription and OTC drugs globally.
We participate in numerous events promoting our portfolio companies and meeting our clients.
CASiGEN Pharma and Guangzhou Institute for Biomedicine and Health, an Institute under the Chinese Academy of Sciences, sign important agreement regarding commercialization of novel drug candidates for the treatment of autoimmune diseases.
Boulder Diagnostics, a VP Portfolio company, announces the European Market Launch of Its SpiroFind™ Lyme Disease Diagnostic Test. For a copy of the relevant press release, follow this link.
Avexxin, a VP portfolio company focusing on the development of novel anti-inflammatory drugs, completes a series B round financing facilitated by Sparebank1 SMN Markets, Norway, with new investors joining existing stakeholders Sarsia Seed and Leiv Eiriksson Nyskaping.
PharmaCellion Ltd, a new portfolio company of Ventac Partners, is a UK based company focusing on the development of novel therapeutic compounds for various cancer indications.
APIM Therapeutics, a Ventac Partners portfolio company, announces closure of a new financing round led by Norsk Innovasjons-kapital III AS, a leading Norwegian VC firm in syndication with existing APIM investors, Sarsia Seed, Birk Venture and Ro Invest.
Windhover Conferences together with the publishers of In Vivo, Startup and the Pink Sheet nominate Avexxin as one of the Top 10 Autoimmune/Anti-Inflammatory companies/Projects to watch.
Idogen AB, a VP portfolio company, originally spun-out from the Biomedical Centre (BMC) at Lund University, Sweden, received a seed-stage investment from Lund University Innovation System (LUIS), Sweden, see http://luis.lu.se/en. Matched by an investment from existing owners, this funding is expected to secure operations until 2013. Idogen is currently developing novel therapeutic approaches for autoimmune diseases and for the prevention of transplant rejection.
CASiGEN Pharma, a VP portfolio company based in Hong Kong, made international news on May 17-18, 2012 with the announcement of a world-wide exclusive license from the Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences (GIBH) to bring diabetes treatments to the global market. The deal marks an important milestone in the use of top-tier healthcare research from mainland China to start a Hong Kong based biotechnology company. A copy of the press release is available here.
Biocentury, a leading biotechnology publication, features APIM Therapeutics in an article published on-line on April 23rd. The article discusses in detail the novel therapeutic approach of the company and its implications for the development of novel cancer therapies. A copy of the article can be downloaded here.